Ventfort (A-3) – a complex peptide compound, research on blood vessels, clinical evidence and limitations

Ventfort is the trade name for a tissue-derived preparation containing a peptide complex. The available documentation does not identify it as a single synthetic peptide with a specific amino acid sequence. The product documentation describes the A-3 peptide complex associated with vascular tissue. Therefore, claims regarding blood vessels, circulation, cholesterol, and aging should be evaluated based on evidence regarding this specific preparation, rather than transferring the results of studies on peptides unrelated to it.[1]

The available literature includes a small clinical report linked to the entity developing the product, published outside the standard scientific literature indexed in PubMed. Its existence means that a statement of complete lack of human observation would be incorrect. However, the reporting method does not allow for confirmation of robust, independently replicated clinical benefits.

The most important questions concern what the studied material contains, what results were measured, and how certain it is that the observed effect can be attributed to this particular preparation.

What is Ventfort? Names, synonyms and identity

For those seeking information about peptides related to blood vessels, the most important thing is to initially distinguish between the trade name and the experimentally identified molecule.

A brand may remain unchanged, even though the suppliers, product features, or production details change. Scientific identification therefore depends on the specific material actually used in the study, and not on general associations related to its name.

This distinction also prevents the accidental citation of studies concerning another product simply because both are described as vascular bioregulators.

The source document can confirm how the authors or producer called the product, but it does not prove that all products sold under that name have the same composition.

The A-3 designation should be presented as an identifier appearing in the product documentation, and not as a chemical abbreviation that allows the structure of a peptide to be reproduced.

Therefore, when evaluating claims, it is necessary to check not only whether the document mentions Ventforța, but also whether it describes a comparable formulation and a result relevant to the subject under analysis.

The names Ventfort and Вентфорт refer to the commercial preparation discussed in this article. On the product page for A-3, the product is listed as a vascular peptide complex.

A-3 is an identifier of the complex, not an amino acid sequence that can be read from the letters and digits.[1]

In the cited clinical document, the material studied was characterized as a fraction with a low molecular mass, obtained from the vascular tissues of young animals, including the aorta.

This information specifies the declared origin of the preparation, but does not provide a complete structural identification of all its components.

The tissue origin of the extract should not be confused with evidence that it selectively reaches the same tissue or causes its regeneration after administration.[2]

The names Ventfort should not be used interchangeably with the names of all vascular peptides, compounds studied in the context of the endothelium, or products sold in the same category of bioregulators.

Different extraction methods and formulations can lead to the production of different materials, even if the claimed source tissue is similar.

Internet descriptions sometimes try to combine branded complexes with specific short synthetic sequences.

Such an association requires traceable primary evidence. The documents used in this article do not justify replacing the identity of the Ventfort complex with a single sequence, the exact mass of the peptide, or the summary pattern derived from information about another substance.

For a specific commercial product, the starting point should be information about the manufacturer, the current formulation, the product category, and the documentation of the respective series.

These data are separate from the question of whether a clinical change was observed in the older report.

How is Ventfort classified? Peptide, protein, mixture or other substance?

The distinction between a defined peptide and a complex is particularly important in peptide educational databases.

A peptide with a specific sequence can be represented using a specific order of amino acid residues and, depending on its chemical form, a calculated molecular mass.

Tissue extract, on the other hand, can contain many chains of varying length and relative quantity.

Calling both preparations peptides is broad enough to be chemically correct, but it hides the differences necessary for proper interpretation of the studies.

The product category is another independent issue.

The labeling of a dietary supplement describes how the product is presented in a specific market. It is not the result of an experimental study confirming its effectiveness against atherosclerosis, fragile capillaries, or another disease.

On the other hand, the mere existence of a clinical report does not automatically convert the supplement into a medicinal product that is allowed for sale.

Every type of claim requires appropriate documentation.

According to the manufacturer’s information, the most substantiated classification for Ventfort is a mixture containing peptides, obtained by extraction from tissues.

It has not been determined that it is a single purified peptide, a single protein, or an endogenous hormone.

The prepared capsule also contains the components of the formulation, therefore its total composition is broader than the peptide fraction itself.[1]

The commercial term „bioregulatory peptide” does not resolve this chemical difference.

It describes the product tradition and the proposed biological role, but does not itself identify the active sequence, the receptor, the exposure profile, or a standardized international category of medicinal product.

On the website analyzed, the products were presented as dietary supplements, not as medicines.

This is important information in the product documentation, but it does not constitute proof of the current legal status or the scope of permitted claims in all countries.

The labeling of a dietary supplement should not be presented as an authorization for the treatment of vascular diseases. [1]

The mixture can be studied with high scientific standards, but repeatability requires appropriate characteristics.

The designation of the preparation as a complex does not prove its ineffectiveness or provide the missing evidence for the proposed action.

The structure and composition of Ventfort – what has been established?

In the case of a mixture, it is better to understand the structural characteristic as a repeatable profile than as a single summary pattern.

Depending on the research question, it can include information on molecular mass distribution, chromatographic profiles, targeted sequence identification, and quantitative markers enabling the comparison of production batches.

None of these techniques need to independently provide a complete list of all ingredients.

Their value lies in enabling the determination of whether the researchers actually analyzed the same material.

Production differences can be significant even when the same tissue is indicated as the source.

The collection of material, extraction, fractionation, purification, storage, and formulation preparation can change the relative amounts of the components recovered.

The original sources do not provide sufficient information to quantify the impact of these factors specifically on Ventfort.

They therefore remain methodological issues, and not demonstrated defects of the preparation.

The correct conclusion is that the analyzed descriptions do not confirm the full equivalence of the composition.

In the clinical document, the fraction was characterized as containing material with molecular masses of up to 5000 Da.

This is the declared upper limit of the mass range of the components, not the molecular mass of a single „molecule of Ventfort”.

On this basis, it is not possible to determine a single summary pattern or a single sequence.[2]

The peptide complex is listed on the product page along with the cellulose carrier, the capsule shell components, and the anti-crystallization substance.

These ingredients are important in distinguishing the active fraction from the entire finished product.

However, they do not provide detailed characteristics of individual peptides.[1]

The scientifically useful characterization should describe the size distribution of peptides, repeatable chromatographic characteristics, significant impurities, and consistency of composition between batches.

If a single sequence is proposed as an explanation for a particular effect, it should be isolated or otherwise identified and examined with appropriate control groups.

The amino acid composition would only answer part of the questions.

It does not allow to determine the order of the remaining compounds, the number of different chains, or the amount of each of them in the mixture.

Two preparations can contain the same building blocks, while at the same time differing in their actual molecular components.

Similarly, the total content of peptides and the chromatographic purity are not interchangeable concepts.

The content designation allows the estimated measured fraction to be estimated, whereas the purity result depends on the analytical method and its ability to detect individual components.

None of these results automatically confirms biological activity, exposure following oral administration, or clinical usefulness.

These restrictions are important when comparing historical products with those currently offered.

Similar brand name, tissue origin or capsule size do not prove that the product studied many years earlier is chemically equivalent to all currently available forms.

Studies on Ventfort – evidence in humans, animals and in the laboratory

A found report on human observations

The two groups described in the report should be presented with their actual numbers: 27 participants in the group receiving Ventfort along with conventional treatment, and 22 people in the comparison group receiving only conventional treatment.

The total number of 49 participants is information about the size of the sample, not a measure of statistical power or the quality of the research methodology.

The diverse clinical picture, including atherosclerosis and plaque scarring, additionally makes it necessary to determine which outcomes were measured in specific participants, rather than assuming that each reported endpoint applied to the entire group.

Since the publication is associated with the entity developing the product, it is particularly important to separate the observations from the authors’ interpretations.

This is not a reason to automatically reject the report.

However, the importance of transparent documentation, independent analysis, and the repetition of results increases.

Without sufficient information about group assignment and previously defined endpoints, visible differences may suggest hypotheses, but they do not allow for a reliable attribution of the causes to the preparation.

The document published in 2011 describes observations collected between 2005 and 2006 among 49 participants aged 52–84 years, who had arterial atherosclerosis or plaque in the legs.

27 people receiving Ventfort in addition to conventional treatment were described, and 22 people receiving only conventional treatment.

The reported results concerned symptoms, lipid measurements, and evaluation of the fragility of the capillaries.

The document is a report related to the entity that developed the preparation, reproduced in a commercial collection of materials, and not a verified publication in a peer-reviewed scientific journal.[2]

The available report does not document sufficient randomization, allocation concealment, blinding, a recorded protocol, or an independently determined primary endpoint.

These are significant gaps in the methodological evaluation, because the participants received basic treatment and differed in terms of clinical conditions.

A study evaluating therapy added to standard treatment can estimate the additional effect if allocation to groups and primary care are appropriately controlled.

Without clear information about these factors, improvement may also result from conventional treatment, baseline differences, participants' expectations, or natural variability.

The lipid table in the report uses a common column of pre-treatment values, and the statistical significance designations refer to a comparison with the baseline values.

Such presentation in itself does not confirm the statistically demonstrated advantage over the control group.

The changes within the group and the treatment effect resulting from the comparison between the groups are separate analyses.[2]

What did the search in scientific databases reveal?

Repeated searches for literature should include the exact product names and appropriate transliterations.

Even then, the lack of results for a specific name does not determine whether the reports exist in local journals, conference proceedings, institutional archives, or commercial collections.

On the other hand, a general search for vascular peptides can yield many studies involving unrelated molecules.

The goal is not to obtain the largest possible number of citations, but to identify studies in which the specified material was actually analyzed.

A targeted search in PubMed for the names Ventfort or Вентфорт did not return any records on the day of the search.

This does not prove the complete absence of research. The unindexed report illustrates precisely the limitations of such a search.

However, this means that the search result did not confirm the existence of extensive clinical research literature on Ventfort that is directly indexed in PubMed. [3]

Animal studies and laboratory tests

Mechanistic claims sometimes appear in the product literature without a fully available primary experiment regarding a specific preparation.

They can be presented as proposed explanations, but they should not be taken as confirmed findings.

Direct evidence would require identifiable research material, an appropriate control group, a documented analytical method, and a measured result.

Research on endothelial cells or vessel damage in a broader context can explain why a particular hypothesis is interesting.

However, they do not confirm that Ventfort produces the same effect.

The found trade materials contain mechanistic claims, but within the scope of this review, the original animal or laboratory study publication to which the claims are attributed has not been directly verified, which would fully characterize the Ventfort material and confirm the proposed vascular mechanism.

This is a limitation of the availability and identification of sources, not proof that no possible experiment has ever been conducted.

Studies on other tissue extracts, defined synthetic peptides, or general endothelial biology can help formulate hypotheses.

However, they cannot constitute direct evidence regarding Ventfort until a link between the materials under investigation is established.

Action mechanisms studied in the context of Ventfort

In this matter, it is easy to confuse several levels of biology.

The endothelial signaling refers to the cells that line the vessels. The intima includes complex lipid, inflammatory, and structural changes. The fragility of the capillaries refers to the reaction of small vessels, whereas the blood lipid concentrations are general measurements.

Even if the preparation changed one of these endpoints, the association of that change with another result would require a separate sequence of experimental evidence.

The mechanism should refer to a real measurement, and not to a general promise of improved circulation.

The oral product introduces an additional question regarding exposure.

Peptides present in the starting material may undergo changes during digestion and metabolism, and the biologically relevant unit may differ from the originally characterized fraction.

The cited materials do not confirm the overall systemic availability of the individual components of Ventfort or their tissue distribution.

Without such information, claims about affecting specific receptors or selectively targeting the vessel wall remain speculative, regardless of whether the product description uses the terminology of tissue affinity.

The main proposed hypothesis is that molecules isolated from vascular tissue could influence biological processes related to the structure or function of blood vessels.

This is a mechanistic hypothesis, not a proven consequence of tissue origin.

To confirm it, researchers would have to link the identified components to exposure, interaction with the molecular target, and a reproducible functional response.

In the case of an oral mixture, an important unresolved issue is which ingredients or metabolites are actually available after administration.

The list of peptides present in the starting material is not the same as the measurement of intact active molecules in the target tissue.

Questions about exposure should not be ignored just because the preparation is described as natural.

Claims regarding cholesterol, microcirculation, the integrity of the vessel wall, and aging of the vascular system also refer to separate processes.

Changes in blood lipid levels do not directly affect the effect on the endothelial receptor.

The result of the fragility test of the fibrous vessels does not indicate a regression of the atherosclerotic plaque.

The improvement in symptoms does not confirm any of these mechanisms.

A useful research program should begin with the repeatable characterization of the material, then include testing specific cellular or tissue hypotheses, and finally combine the results with clinically relevant endpoints.

The evidence found does not cover the entire series of studies for Ventfort.

Therefore, this article does not present Ventfort as a preparation with proven ability to regenerate blood vessels, remove atherosclerotic plaques, prevent heart attacks, or prolong life.

These are separate claims that require direct and much stronger evidence than the general assumptions regarding peptide bioregulators.

Limitations of scientific evidence regarding Ventfort

The uncertainty stems from several overlapping constraints, not from a single missing element of the study.

The lack of a fully characterized mixture makes it difficult to repeat the experiments. A small comparative study with treatment added to conventional therapy makes it difficult to attribute causality. However, results such as cholesterol or the fragility of the capillaries of the skin cannot replace measurements of cardiovascular events prevention.

These restrictions affect each other.

For example, a later study using a different formulation would not necessarily invalidate the earlier clinical claim if comparability of the materials was not demonstrated.

The interpretation of risk also requires an appropriate number of participants and sufficient observation time.

A small study can report whether certain events occurred during the observation, but it does not allow to reliably rule out rare complications or characterize the long-term effects.

The reviewed materials do not justify a quantitative determination of the frequency of adverse events, a universal claim about safety, or a conclusion regarding the interaction with drugs used in vascular diseases.

The absence of detailed reporting should be presented as uncertainty, rather than as a positive safety outcome.

The first main uncertainty concerns molecular identity and repeatability.

A complex without a complete profile of components is more difficult to compare between studies and formulations than a molecule with a defined sequence.

Each clinical interpretation depends on the level of certainty that the appropriate material can be produced in a reproducible manner.

The second limitation is the scarce information about the clinical trial project.

A small report linked to the entity developing the product can serve as a starting point for further research, but it does not replace independently replicated controlled studies.

Work by non-indexed authors should not be dismissed solely because of the place of publication. Their methods should be evaluated.

At the same time, the publication of the report in a professionally-looking collection of materials does not confirm its methodological quality.

The third limitation is the replacement of one endpoint with another.

Laboratory results and reported symptoms are not equivalent to cardiovascular events, disability, or mortality.

The claim that the product prevents a serious clinical event requires evidence measuring that event or an appropriately justified, validated surrogate endpoint under appropriate conditions.

The uncertainty regarding security also remains significant.

A short report without systematically documented adverse events cannot rule out rare reactions, interactions, or problems in populations that have not been adequately studied.

The absence of an observed event in a small sample does not prove its absence in a larger population.

The equivalence of all current product forms or their regulatory status in individual countries has also not been confirmed.

Consumer opinions, trade certificates, and ingredient descriptions answer questions other than controlled clinical trials.

They should not be used to fill in gaps in evidence regarding efficacy or safety.

Most frequently asked questions about Ventfort

1. Does Ventfort mean one of the defined substances?

The analyzed documents describe a peptide complex, not a single molecule with a specific sequence. The product name identifies the preparation, while the full identity of its components remains a separate analytical issue. The summary pattern or short sequence assigned to another peptide should not be used in reference to the entire complex. [1] Therefore, in the scientific database, the most precise entry is a complex with unfully described sequences of its components, not a single peptide with an unconfirmed chemical formula.

2. What do the available studies on Ventfort confirm?

They confirm the existence of a small report of human observations linked to the entity developing the product, but not a well-replicated clinical benefit. The study documentation requires critical evaluation of the comparison and reporting method. Its existence should be taken into account without presenting it as conclusive evidence of the efficacy of treating vascular diseases. [2] The available information justifies discussing historical observations and their limitations, rather than claiming proven prevention or treatment of cardiovascular diseases.

3. Is A-3 an amino acid sequence?

No. The A-3 product documentation identifies a peptide complex. This code does not specify the length of the chain or the order of the amino acid residues. Structural claims require actual analytical information, not an interpretation of the product identifier. [1] Treating A-3 as if it represented three amino acid residues or a specific sequence would lead to the unwarranted assignment of a precise structure.

4. Does the origin from vascular tissue confirm the selective delivery to the vessels?

No. The source tissue of the extract does not specify where its components are transported after administration. Selective delivery requires evidence of distribution and functional activity. The tissue origin may serve as a basis for the hypothesis, but does not replace experimental verification. To confirm the targeted effect, researchers would have to detect the appropriate molecules at the proposed site of action and demonstrate a significant response specific to that tissue.

5. Is Ventfort the same as every vascular bioregulator?

No. A broad category of trade can include chemically different extracts and synthetic substances. Similar claimed uses do not confirm equivalent composition or exposure. Evidence regarding another preparation should remain indirect until a significant link between the materials is demonstrated. The term „vascular” may describe the intended area of study, without proving that different commercial products contain the same active ingredients.

6. Does the value 5000 Da identify one molecule of Ventfort?

No. It describes the declared upper bound of the molecular mass range of the extract fractions. The mixture may contain many components below this limit. Therefore, the values of this should not be presented as the exact molecular mass of Ventfort. [2] The upper bound of the size may include numerous peptides and other molecules, so it should not be used to calculate a single molar concentration for the entire mixture.

7. Does the lack of results in PubMed prove that there are no observations in humans?

No. Reports may appear outside PubMed or under other names. A commercially available collection of materials includes human observations despite the lack of search results for the exact name. The relevant point is the availability of sources and the quality of the evidence, not the complete absence of studies. [3] Indexing status is a property of the search method. After finding a document, the quality of the studies still needs to be evaluated separately.

8. Was the found clinical report a randomized controlled trial?

The available report does not sufficiently document the random allocation to groups or the other methodological safeguards necessary to characterize it as a randomized study. The mere presence of a control group does not imply randomization. Therefore, the report should be described according to what its methods actually document. The presence of a comparator is helpful, but the manner of allocation, blinding, and choice of endpoints determine how convincingly the study supports the causal conclusion.

9. Can the improvement during conventional treatment be entirely attributed to Ventfort?

No. Primary treatment and other differences can affect the outcome. A well-controlled trial of additional therapy can estimate the additional effect, but requires clear allocation to groups, comparable care, and appropriate analysis. Improvement after introduction of the product does not automatically allow for its contribution to be isolated. Without such safeguards, a beneficial change may reflect care received by both groups, rather than a separate additional effect.

10. Does a change in cholesterol levels indicate the regression of the atherosclerotic plaque?

No. Measuring blood lipids is not a direct measure of the size of the plaque or the structure of the artery. Even a confirmed change in one endpoint would require appropriate evidence before drawing conclusions about the other. Therefore, mechanistic and clinical claims should be formulated separately. A direct assessment of the plaque would require imaging or other validated methods of measuring arterial structure.

11. Does reducing the fragility of capillaries in the hair follicles prove to prevent heart attacks?

No. The assessment of fragility of the capillaries and serious cardiovascular events are different endpoints. The outcome regarding skin changes associated with small vessels does not confirm the prevention of coronary events. Such claims require directly relevant clinical evidence, not anatomical analogy. The prevention of myocardial infarction is an important endpoint for the patient, which requires much more direct evidence than a vascular test performed on the skin.

12. Do the changes before and after the treatment indicate an advantage over the control group?

No. A statistically significant change within the group does not confirm a significant difference between the groups. The analysis must verify the actual comparison of treatment effects, taking into account the baseline values and uncertainty. This distinction is particularly important when the tables present common baseline data or incomplete information regarding individual groups. An appropriate analysis should assess the differences between the groups, preferably with uncertainty intervals and a previously defined statistical plan.

13. Does the amino acid list identify active peptides?

No. It specifies building blocks, not complete molecular sequences. The length of chains, the order of connections, and the relative amount of components can vary between mixtures with similar amino acid composition. Therefore, the mechanism attributed to a specific component requires more detailed evidence. Identifying the individual components would help verify whether a specific molecule is associated with a reproducible biological response.

14. Does the natural origin of Ventfort guarantee safety?

No. Biological origin does not confirm the safety of the product, its impurities, or the formulation. Safety requires evidence of actual material and appropriate exposure. The reassuring description does not replace a systematic assessment of adverse events. Important questions concern impurities, variability between batches, interactions, and adequately documented adverse effects in the population for which the product is intended.

15. Are the capsules and other characters from Ventfort interchangeable?

Equivalentity cannot be assumed based on a common name. The formulation, stability, amount of ingredients, and exposure may vary. Comparison requires documentation of the specific product and appropriate evidence, not a general statement that each formulation contains peptides. Even if two formulations bear the same A-3 name, their absorption and ingredient stability may be different.

16. Can consumer opinions confirm the Ventfort vascular mechanism?

No. Reviews do not usually verify the identity of the product, do not measure molecular targets, or control concomitant treatment. They may describe individual experiences, however causality remains undetermined. The mechanism requires experimental evidence, and clinical efficacy requires appropriate clinical comparison. User reports cannot determine whether observed changes are due to the product, concomitant medical care, or unrelated variability.

17. Which studies would most increase the credibility of claims regarding Ventfort?

The greatest improvements in certainty would be achieved through reproducible compositional characteristics and independently repeated controlled studies. These should include a clearly defined population, clinically relevant results, and a systematic safety assessment. Transparent exposure data would also help to link the mixture to the proposed mechanism, rather than relying on assumptions derived from tissue origin.

Applications

The most important distinction concerns the traceable description of the product and the independently demonstrated clinical effect.

The origin of Ventfort from vascular tissue and the designation A-3 allow the object to be identified in existing reports, but they do not prove the selective delivery of components to the vessels.

A small comparison with the participation of people provides historical observations, but does not determine whether the product changes the progression of arterial diseases or the frequency of serious cardiovascular events.

More convincing evidence would require combining consistent material characteristics with well-controlled, transparent human studies, focused on specific indications.

Ventfort should be understood as a trademark peptide mixture derived from vascular tissue, rather than as a chemically verified single peptide with a specific sequence.

There is a small, unindexed report of observations in humans; however, its methods and reporting style leave significant uncertainty regarding the attribution of effects and their clinical significance.

A reliable description should maintain this distinction and avoid conveying evidence regarding unrelated vascular peptides or general claims about bioregulators.

Independent replication of the results and clinically relevant endpoints would be particularly valuable, because the existing report covers a small group and is linked to the entity developing the product.

Educational and medical reservation

The article is intended for educational and scientific purposes only and does not constitute medical advice or recommendations for the use of Ventfort. It does not present dosage regimens, preparation or administration instructions.

Available studies do not unequivocally confirm the effectiveness or safety of Ventfort in the treatment of atherosclerosis, circulatory disorders, or other vascular diseases. Natural origin does not guarantee safety, and regulatory status depends on the country and the specific product.

Cardiovascular problems require professional medical evaluation. This article should not be used to independently change the recommended treatment.

References

1. Peptides. (n.d.). Ventfort [Ventfort]. Retrieved October 23, 2026, from https://peptides1.ru/products/health/citomaxes/ventfort/
2. Medical Center of the St. Petersburg Institute of Bioregulation and Gerontology. (2011). Report on the results of clinical studies of the biologically active food supplement Ventfort [English translation in a commercial compilation, PDF pp. 12–15]. Retrieved October 23, 2026, from https://peptidi-slo.si/wp-content/uploads/2023/12/brosura-3.pdf
3. National Library of Medicine. (n.d.). PubMed search: Ventfort OR Ventsfort. Retrieved October 23, 2026, from https://pubmed.ncbi.nlm.nih.gov/?term=Ventfort+OR+%D0%92%D0%B5%D0%BD%D1%82%D1%84%D0%BE%D1%80%D1%82